Product image of Mytolac (Lanreotide Acetate) supplied by GNH India

Mytolac

Active Ingredient:
Lanreotide Acetate
Origin:
EU

Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a sterile solution for subcutaneous use. It reduces excess growth hormone secretion in patients with acromegaly and inhibits hormone release from neuroendocrine tumors, helping to control disease progression.

GNH India supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Amdipharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mytolac, a somatostatin analog, is used in endocrine and neuroendocrine disease pathways.

  • Acromegaly: lowers elevated growth hormone levels and can reduce pituitary tumor size.
  • Gastroenteropancreatic neuroendocrine tumors: controls hormone secretion and slows tumor progression.
  • Carcinoid syndrome associated with neuroendocrine tumors: alleviates flushing and diarrhea caused by excess peptide release.

How It Works

  • Lanreotide acetate is a synthetic analogue of somatostatin that binds with high affinity to somatostatin receptor subtypes (SSTR2, SSTR5). Receptor activation inhibits adenylate cyclase activity, reducing cyclic AMP formation and suppressing the secretion of growth hormone, insulin, glucagon, and various peptide hormones released by neuroendocrine tumors, thereby controlling disease activity.

Side Effects

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Diarrhea: loose stools occurring after administration.
  • Abdominal pain: cramping or discomfort in the abdomen.
  • Nausea: feeling of sickness without vomiting.
  • Hyperglycemia: elevated blood glucose levels.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Gallstones: formation of biliary calculi requiring medical attention.
  • Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain.
  • Severe hyperglycemia: markedly high blood glucose requiring intervention.
  • Allergic reactions: rash, itching, or anaphylaxis in rare cases.
  • Cardiac arrhythmia: irregular heart rhythm observed in susceptible patients.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for potential complications.

  • Glucose monitoring: regularly check blood sugar as lanreotide may affect glycemic control.
  • Gallbladder assessment: evaluate for gallstones or biliary disease prior to treatment.
  • Pituitary tumor evaluation: assess tumor size and visual fields before and during therapy.
  • Renal function: adjust use in patients with significant renal impairment.
  • Hypersensitivity: avoid in individuals with known allergy to lanreotide or formulation components.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Cyclosporine: may increase lanreotide concentrations, risking toxicity.
  • Concurrent somatostatin analogs: additive hormonal suppression can lead to severe side effects.
  • Insulin or oral hypoglycemics: may require dose adjustments due to altered glucose metabolism.

Moderate Interactions (Monitor Closely)

  • Glucocorticoids: can exacerbate hyperglycemia when combined with lanreotide.
  • Dopamine agonists: may influence hormonal balance and require monitoring.
  • QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias.

Frequently Asked Questions

Mytolac is prescribed for patients with acromegaly to lower excess growth hormone and for those with neuroendocrine tumors, including gastroenteropancreatic NETs and carcinoid syndrome, to control hormone secretion and disease progression.

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors, mainly SSTR2 and SSTR5. This binding blocks adenylate cyclase, reduces cyclic AMP, and suppresses the release of growth hormone and other peptide hormones, thereby managing the underlying disease.

The dosage of Mytolac is individualized by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. The prescriber determines the appropriate amount, frequency, and duration of treatment.

The safety of Mytolac in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mytolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mytolac (lanreotide acetate) and other somatostatin analogs such as octreotide share a similar mechanism of receptor binding but differ in dosing frequency, formulation, and pharmacokinetic profile. Lanreotide often allows for longer dosing intervals, which can improve patient convenience compared with some alternatives.

Mytolac should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for use to maintain stability.

Mytolac is given as a subcutaneous injection by a healthcare professional. The injection is typically performed in the abdomen, thigh, or upper arm, following aseptic technique and the specific dosing schedule prescribed by the treating physician.

Serious risks include the development of gallstones, pancreatitis, severe hyperglycemia, allergic reactions such as anaphylaxis, and cardiac arrhythmias. Patients should be monitored regularly for these events, and any concerning symptoms should be reported to a healthcare provider promptly.

Mytolac is contraindicated in individuals with known hypersensitivity to lanreotide acetate or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled diabetes, or active gallbladder disease, and the decision to treat should be made by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT